Neurol. pro Praxi, 2007; 2: 112-117

Inhibitory cholinesteráz v léčbě alzheimerovy nemoci

MUDr. Martin Brunovský
Psychiatrické centrum Praha, 3. LF UK, Praha

Hlavním cílem současné symptomatické léčby Alzheimerovy choroby (AD) zůstává oddálení progrese symptomů nemoci zvýšením cholinergní neurotransmise pomocí inhibitorů cholinesteráz (IChE). Důležitými ukazateli okamžité i dlouhodobé účinnosti, bezpečnosti a snášenlivosti různých IChE je specifita jejich inhibiční aktivity, selektivita vůči AD – relevantním molekulárním izoformám cholinesteráz, selektivita vůči mozku a periferní tkáni a v nemalé míře i jejich farmakokinetický profil. Článek přináší stručnou deskripci jednotlivých typů cholinesteráz, jejich funkcí a možnostech jejich inhibice. V souvislosti s léčbou IChE se článek zaměřuje na projevy cholinergního deficitu z hlediska kognitivních funkcí a také na rozdílné profily tolerance a spektra nežádoucích účinků jednotlivých IChE, a to z hlediska akutní i dlouhodobé léčby.

Keywords: Alzheimerova nemoc, inhibitory cholinesteráz, léčba, nežádoucí účinky

Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brunovský M. Inhibitory cholinesteráz v léčbě alzheimerovy nemoci. Neurol. praxi. 2007;8(2):112-117.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anand R, Messina J, Hartman R, et al. Maximising functional ability: new data with cholinesterase inhibitors. Int J Psychogeriatr 1999; 11 (suppl. 1): 86.
    2. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986; 47: 263-277. Go to original source... Go to PubMed...
    3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006; 1: CD005593. Go to original source... Go to PubMed...
    4. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001190. DOI: 10.1002/14651858.CD001190. pub2. Go to original source... Go to PubMed...
    5. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2000,Issue 4.Art.No:CD001191. DOI: 10.1002/14651858. CD001191. Go to original source...
    6. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-27. Go to original source... Go to PubMed...
    7. Carcenac D, Martin-Hunyadi C, Kiesmann M et al. Extra-pyramidal syndrome induced by donepezil. Presse Med 2000; 29 (18): 992-993. Go to PubMed...
    8. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nature Rev Neurosci 2003; 4: 131-138. Go to original source... Go to PubMed...
    9. Doody RC, Stevens JC, Beck RN, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the Amerian Academy of Neurology. Neurology 2001; 56: 1154-1166. Go to original source... Go to PubMed...
    10. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuro-Psychoph 2002; 26: 705-712. Go to original source... Go to PubMed...
    11. Grossberg GT, Stahelin HB, Messina JC at al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000; 15 (3): 242-247. Go to original source...
    12. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract 2002; Suppl 127: 45-63.
    13. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11 (suppl 5): 31-61. Go to original source... Go to PubMed...
    14. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol. 2006; 9 (1): 101-124. Go to original source... Go to PubMed...
    15. Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 2003; 49: 55-60. Go to original source... Go to PubMed...
    16. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001747. DOI: 10.1002/14651858.CD001747.pub3. Go to original source... Go to PubMed...
    17. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract 2002; Suppl 127: 6-19.
    18. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung 2003; 54: 183-189. Go to original source... Go to PubMed...
    19. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210-216. Go to original source... Go to PubMed...
    20. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurology 2007; 14: e1-e26. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.